Charles Henry Noble

US Patent:

20210008091, Jan 14, 2021

Filed:

Dec 24, 2019

Appl. No.:

16/726624

Inventors:

- San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US
Francis C. SZOKA - San Francisco CA, US

International Classification:

A61K 31/7048
A61K 9/127
A61K 31/395
A61K 31/704
A61K 9/19
A61K 31/337
A61K 31/4196
A61K 31/496
A61K 38/07
A61K 47/02

Abstract:

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (

US Patent:

20190314282, Oct 17, 2019

Filed:

Jun 27, 2019

Appl. No.:

16/454555

Inventors:

- San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US

International Classification:

A61K 9/127
B01J 13/08
A61K 31/5377
A61K 31/4196
A61K 9/00
A61K 38/07
A61K 31/496

Abstract:

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (

US Patent:

20190110991, Apr 18, 2019

Filed:

Sep 10, 2018

Appl. No.:

16/126799

Inventors:

- San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US

International Classification:

A61K 9/127
A61K 31/4196
A61K 31/496
A61K 38/07
A61K 9/00
A61K 31/5377
B01J 13/08
A61K 9/19

Abstract:

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (

US Patent:

20180296484, Oct 18, 2018

Filed:

Oct 15, 2016

Appl. No.:

15/768352

Inventors:

- Wrexham, GB
- Cambridge MA, US
Mark Eamon Hayes - MILL VALLEY CA, US
Charles Noble - SAN FRANCISCO CA, US
Kevin Kesper - WATERTOWN MA, US
Antoine M. Awad - WEST ROXBURY MA, US
Douglas J. Moore - NEWTON MA, US
Andrew J. O'Brien - FRANKLIN MA, US

International Classification:

A61K 9/127
A61K 31/4745

Abstract:

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

US Patent:

20170239182, Aug 24, 2017

Filed:

Aug 12, 2015

Appl. No.:

15/503004

Inventors:

Mark E. HAYES - San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US
- San Francisco CA, US

International Classification:

A61K 9/127
A61K 31/4196
A61K 31/16

Abstract:

The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can also contain essential trace metals to compensate for the off target effect of removal of endogenous non-target trace metals by administration of the chelator. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.

US Patent:

20170231910, Aug 17, 2017

Filed:

Aug 12, 2015

Appl. No.:

15/503001

Inventors:

Mark E. HAYES - San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US
- San Francisco CA, US

International Classification:

A61K 9/127
B01J 13/08
B01J 13/20
A61K 31/16
A61K 31/4196

Abstract:

The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can also contain essential trace metals to compensate for the off target effect of removal of endogenous non-target trace metals by administration of the chelator. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.

US Patent:

20170224715, Aug 10, 2017

Filed:

Aug 4, 2015

Appl. No.:

15/502092

Inventors:

- San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US
Francis C. SZOKA - San Francisco CA, US

International Classification:

A61K 31/7048
A61K 9/19
A61K 47/02
A61K 31/496
A61K 31/4196
A61K 31/337
A61K 9/127
A61K 38/07

Abstract:

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (

US Patent:

20170202776, Jul 20, 2017

Filed:

Feb 9, 2017

Appl. No.:

15/429113

Inventors:

- San Francisco CA, US
Charles O. NOBLE - San Francisco CA, US

International Classification:

A61K 9/127
B01J 13/08
A61K 31/496
A61K 31/4196
A61K 38/07
A61K 9/00

Abstract:

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (